Actively Recruiting
Egyptian Hypertrophic Cardiomyopathy Program
Led by Magdi Yacoub Heart Foundation · Updated on 2023-06-01
2000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting the Egyptian Hypertrophic Cardiomyopathy (HCM) Program to understand the incidence, severity, and characteristics of HCM in Egypt. The study also aims to explore genetic factors and the underlying molecular and cellular mechanisms that influence the disease's different forms. A key focus is on patients who have genetic markers but no symptoms, which may provide insight into how the disease develops. The program involves detailed characterization of patients and their relatives through clinical, genetic, and laboratory assessments. It includes training for Egyptian medical professionals in advanced diagnostic and treatment techniques. The study uses state-of-the-art medical, surgical, and interventional methods tailored to each patient's condition, with ongoing collection and analysis of human tissue samples from surgical procedures. Participants will undergo regular follow-ups approximately once per year, over an average of five years, to monitor disease progression and severity through clinical exams, imaging, and genetic testing. The study measures include the incidence of HCM, clinical severity, cardiac phenotype, and genotype correlations. This long-term observation aims to improve understanding and management of HCM in Egypt while supporting advanced training and research development.
CONDITIONS
Brief Title
Egyptian Hypertrophic Cardiomyopathy Program
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with hypertrophic cardiomyopathy who are willing and consent to participate.
- Family members of these patients who are willing and consent to participate.
You will not qualify if you...
- Refusal to consent to participate in the registry program.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants are observed over time to define the incidence, severity, phenotype, and genotype of hypertrophic cardiomyopathy, as well as to study disease mechanisms.
Approximately 5 visits, about 1 visit per year
Trial Site Locations
Total: 1 location
1
Aswan Heart Centre - Magdi Yacoub Heart Foundation
Aswān, Egypt
Actively Recruiting
Research Team
M
Magdi H Yacoub, FRS OM
S
Shehab M Anwer, MBBCh., MRes
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here